DIRS.INFO The most relevant business & tech news

☆ I got laid off at 65 and couldn't afford my Bay Area mortgage. Now, I work for myself while traveling the world.
▼ + stars: | 2024-08-06 | by ( Tony Woodall | ) www.businessinsider.com time to read: +6 min

Read previewI began my career in the financial services industry in 1985 in the warehouse at Fannie Mae Software Systems. I moved to the Bay Area and began my subsequent career in financial services. We couldn't recover before the Federal Reserve took us into receivership, making us the second-largest bank failure in history. The biggest problem was my homeWithout a full-time job, I could no longer afford the mortgage on my home in the Bay Area. Tony WoodallAfter Portugal, I joined friends in Medellín, Colombia, an inexpensive haven for digital nomads.

Persons: —, Tony Woodall, Woodall, you'll, I'm, I've Organizations: Service, Fannie Mae Software Systems, Business, realtors, Bank, LinkedIn, Bay Area, First Republic, Federal Reserve, Social Security Locations: Fannie, Atlanta, San Francisco, Bay, Silicon, California, Camino de Santiago, Spain, Portugal, Portuguese, Colombia, Medellín, Germany

☆ World Cup 2023: Previous World Cup finals
▼ + stars: | 2023-10-25 | by ( ) www.reuters.com time to read: +5 min

PARIS, Oct 25 (Reuters) - On Saturday, New Zealand take on South Africa in the 2023 Rugby World Cup final at the Stade de France, with both teams hoping to win a record fourth title. Mapimpi scored the first try in the 66th minute, becoming the first Springbok to score a try in a World Cup final, despite South Africa having won two previous titles. The teams had met in the pool stage with South Africa winning 36-0. Fullback Jonathan Webb scored two penalties for England, whose decision to ditch their forward-reliant tactics for an expansive running game backfired. 1987 - NEW ZEALAND 29 FRANCE 9 (AUCKLAND)The All Blacks laid down the marker in the first World Cup final, dominating from start to finish as flyhalf Grant Fox's kicking helped his team gain territory time and again.

Persons: Makazole, Cheslin Kolbe, Handre Pollard, Mapimpi, Richie McCaw, Flyhalf Dan Carter, Beauden Barrett's, Tony Woodcock, Stephen Donald, Percy Montgomery, Francois Steyn, Alain Rolland's, Mark Cueto, England's Jonny Wilkinson, Australia's Elton Flatley, Wilkinson, Matt Burke, Ben Tune, Owen Finegan, Nelson Mandela, Jonah Lomu, Joel Stransky's, Webb Ellis, Tony Daly, Michael Lynagh, Fullback Jonathan Webb, flyhalf Grant Fox's, Michael Jones, David Kirk, John Kirwan, Pierre Berbizier, Rohith Nair, Aadi Nair, Christian Radnedge Organizations: Stade de France, England, Springbok, South, Blacks, Wallabies, Springboks, South Africa, ZEALAND, Fullback, Fox, Thomson Locations: New Zealand, South Africa, ENGLAND, YOKOHAMA, Japan, AUSTRALIA, TWICKENHAM, FRANCE, AUCKLAND, France, PARIS, England, SYDNEY, CARDIFF, Australia, JOHANNESBURG, Bengaluru

☆ RSV vaccine from GSK shows potential to protect adults 50 to 59
▼ + stars: | 2023-10-25 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +1 min

A vaccine from GlaxoSmithKline showed the potential to protect adults ages 50 to 59 from respiratory syncytial virus in a late-stage clinical trial, the company said Wednesday. Currently, Arexvy is approved in the U.S., Europe, Japan and other countries for adults ages 60 and older. A single dose of the British drugmaker's shot elicited an immune response in adults ages 50 to 59 who are at an increased risk of catching RSV due to certain underlying medical conditions. The immune response wasn't worse than that observed in adults 60 and above, GSK said in a release. Safety data in adults ages 50 to 59 was also consistent with data in adults 60 and above, according to GSK.

Persons: Tony Wood Organizations: GlaxoSmithKline, Arexvy, GSK, Food and Drug Administration Locations: U.S, Europe, Japan, British

☆ How GSK plans to replenish its depleted medicine cabinet
▼ + stars: | 2023-03-15 | by ( Maggie Fick | ) www.reuters.com time to read: +6 min

GSK has since suffered a series of clinical trial setbacks in its cancer drugs portfolio, most recently last year involving ovarian cancer drug Zejula and blood cancer drug Blenrep. BLOCKBUSTER POTENTIALAnalysts say that despite a string of strong quarterly earnings, lingering concerns over the company's drug pipeline reflect in GSK's share price. The investor said he does not see enough GSK drugs, either on the market or in development, with potential to be a so-called "blockbusters" with annual sales exceeding $1 billion. But Wood said the overhauled R&D department has put GSK in a strong position to meet growth targets. U.S. regulatory approval on GSK's vaccine, and a rival vaccine developed by Pfizer, is expected in May.

☆ With positive combo meningococcal vaccine data, GSK eyes US approval
▼ + stars: | 2023-03-14 | by ( ) www.reuters.com time to read: +3 min

If approved, the combo vaccine could simplify the immunisation schedule in the United States and likely expand GSK's already dominant market share there for vaccines used to prevent illnesses caused by meningococcal bacteria. These responses were compared to participants who received GSK's approved vaccines, Bexsero and Menveo. In the United States, a four-shot regimen of Bexsero and Menveo is needed to protect against the five most common strains of meningococcal bacteria. There is no combination vaccine on the market - a gap GSK intends to fill with the new combination. GSK has the world's largest vaccine R&D department and has a broad portfolio of shots, including its blockbuster shingles vaccine Shingrix.

☆ Children’s health leaders call for emergency response as respiratory viruses continue to spread across the US
▼ + stars: | 2022-11-18 | by ( Deidre Mcphillips | ) edition.cnn.com time to read: +7 min

And health care systems nationwide continue to feel the strain of a respiratory virus season that has hit earlier and harder than usual. There have been about 8 flu hospitalizations for every 100,000 people this season – rates typically seen in December or January. While the Covid-19 emergency declaration remains in place, the federal government has not made a formal emergency declaration around children’s health care. HHS and the CDC are in regular contact with health care leaders and providers, actively monitoring situational needs and ready to provide assistance on a case-by-case basis, an HHS spokesperson told CNN. They also urge all those eligible to get their flu and Covid-19 vaccines, along with other routine vaccinations.

☆ GSK says key trial data shows its RSV vaccine is 'truly exceptional'
▼ + stars: | 2022-10-13 | by ( ) www.reuters.com time to read: +1 min

LONDON, Oct 13 (Reuters) - Late-stage data unveiled on Thursday showed GSK's respiratory syncytial virus (RSV) vaccine was 82.6% effective in a keenly watched late-stage study involving older adults. The trial, which involved roughly 25,000 adults aged 60 and over, tested a single dose of the experimental vaccine against a placebo. Register now for FREE unlimited access to Reuters.com RegisterVaccine efficacy against severe lower respiratory tract disease (LRTD) associated with an RSV infection was 94.1%, the British drugmaker said. GSK is a key player in the race to develop a safe and effective RSV vaccine, which, if approved, is expected to generate billions in sales for its maker. Register now for FREE unlimited access to Reuters.com RegisterReporting by Natalie Grover; Editing by Mark Potter and Jan HarveyOur Standards: The Thomson Reuters Trust Principles.

☆ RSV vaccine race heats up with highly effective GSK shot
▼ + stars: | 2022-10-13 | by ( Natalie Grover | ) www.reuters.com time to read: +3 min

LONDON, Oct 13 (Reuters) - Data unveiled on Thursday showed GSK's (GSK.L) respiratory syncytial virus (RSV) vaccine was 82.6% effective in a keenly watched late-stage study involving older adults. The company is a key player in the race to develop a safe and effective RSV vaccine, which, if approved, is expected to generate billions in sales for its maker. If approved, Jefferies analysts have forecast $2.5 billion in global RSV vaccine peak sales in older adults for GSK. U.S. drugmaker Pfizer (PFE.N) in August disclosed positive Phase III data on its rival RSV vaccine in older adults. In trial participants with pre-existing conditions, the GSK vaccine was shown to be 94.6% effective, while in adults aged 70 to 79 it was 93.8% effective, the company said.

☆ How to Stay Safe in the Heat
▼ + stars: | 2022-07-20 | by ( Christine Hauser | The New York Times | ) www.nytimes.com time to read: +21 min

How to Stay Safe in the Heat Give this articleImage People flocked to Alki Beach in Seattle in June 2021 to escape the heat. Rising temperatures can put many at risk for heat-related illnesses, including heat stroke and heat exhaustion. Here’s guidance from experts on how to stay cool during the swelter — even without air-conditioning. There are a few tips to keep in mind to stay hydrated during a heat wave, when people should be especially vigilant about keeping themselves safe and healthy. Trying to stay cool during a heat wave in Houston in June.

Persons: Ruth Fremson, It’s, Kelly Hyndman, Leslie Swanson, Dr, Swanson, ”, Philip Gehrman, Justin Fiala, “ You’re, Fiala, Brandon Bell, Juan Arredondo, Basil Eldadah, Sharon A, Brangman, Eldadah, James Mark, Claire McCarthy, haven’t, “, they’re, Tony Woodward Organizations: New York Times, Northern, Centers for Disease Control, University of Alabama, Getty, University of Michigan, Penn Sleep Center, University of Pennsylvania, New York Times Company, Northwestern Medicine, ., The New York Times, National Institute, Aging, SUNY, Medical University, Cleveland Clinic, Boston Children’s Hospital, Harvard Medical School, Seattle Children’s Locations: Alki, Seattle, Europe, Birmingham, Houston, United, geriatrics, Syracuse, N.Y, Ohio, Boston

Search resuls for: "Tony Wood"

9 mentions found